small molecule

SYNRIBO

OMACETAXINE MEPESUCCINATE

Loss of exclusivityOctober 2026latest FDA-listed patent expiry
CompanyTEVA PHARMACEUTICALS INTERNATIONAL GMBH

Drug detail

Brand nameSYNRIBO
Active ingredientOMACETAXINE MEPESUCCINATE
Strength3.5MG/VIAL
Dosage formPOWDER
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalOctober 2012
Marketing statusDISCN

Listed patents

PatentExpiresType
6987103October 2026use U-1300

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SYNRIBO patent cliff — loss of exclusivity October 2026 | CliffBio